Pasar al contenido principal

Mechanisms of cancer progression and therapy resistance at the single cell level

RYC2019-027726-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Ramón y Cajal
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Engineering a single-chain immunoglobulin scaffold loaded with a latent-releasable cytotoxic pore-forming peptide

  • Morillo, Izaskun
  • Zulaica, Joao
  • Ramos Caballero, Asier
  • Auzmendi-Iriarte, Jaione
  • Largo, Eneko
  • Apellániz, Beatriz
  • Carracedo, Arkaitz
  • Piva, Marco
  • Nieva, José Luis
  • Rujas, Edurne
Pore-forming peptides (PFPs) hold strong anti-tumor potential but require delivery systems to ensure stability and prevent off-target effects. In this study, we develop a strategy to transport a PFP in a biologically latent, precursor-like state. Specifically, based on the therapeutic antibody atezolizumab, which targets the tumor-associated programmed death-ligand 1, we engineered a single-chain IgG (scIgG) construct with flexible linkers embedding the melittin sequence. To further enable tumor-specific activation, melittin was flanked by regions cleavable by matriptase/ST14 (MT), a protease overexpressed in carcinomas. Initial constructs failed due to cytotoxicity during expression, prompting the redesign of melittin into a variant named Pmod2-2. This peptide retained potent pore-forming ability and was compatible with IgG fusion. The resulting scIgG-Pmod2-2 hybrid preserved Fab and Fc functionalities of the atezolizumab IgG, displayed favorable pharmacokinetics and released the active peptide in response to MT. These results highlight the potential of integrating cytolytic PFPs into antibody-based therapeutics., This study was supported by grants PID2021-126014OB-I00, PID2021-122212OA-I00, PID2022-141200OA-I00, and PID2022-141553OB-I0 (FEDER/EU) funded by MCIN/AEI/10.13039/501100011033/FEDER, UE. Additional support was provided by the European Research Council (Consolidator Grant 819242). J.A. and M.P. acknowledge research contracts from the Ministry of Science and Innovation of Spain (JDC2023-052498-I funded by MICIU/AEI /10.13039/501100011033 and FSE+ and RYC2019-027726-I funded by MICIU/AEI /10.13039/501100011033 and El FSE invierte en tu futuro). I.M. and J.Z. acknowledge predoctoral contracts from the Basque Government, while E.R. received funding from the ERC (grant H2020-MSCA-COFUND-2020-101034228-WOLFRAM2)., Peer reviewed